01447nas a2200541   4500000000100000000000100001000000100002008004100003653001100044653003000055653003100085653003000116653005300146653002600199653001900225653001800244653003100262653003900293653004500332653001100377653001200388653001900400653002500419653001700444653001800461653001700479100001500496700001400511700001100525700001600536700001400552700001200566700001100578700001900589700001400608700001500622700001300637700001500650700001700665700001300682700001100695700001500706245013600721250001500857300001200872490000700884020001400891       2023                            d10aHumans10a*Losartan/therapeutic use10aIrbesartan/therapeutic use10aValsartan/therapeutic use10aAngiotensin Receptor Antagonists/therapeutic use10aRetrospective Studies10aCohort Studies10a*Hypertension10aTetrazoles/therapeutic use10aBiphenyl Compounds/therapeutic use10aangiotensin-converting enzyme inhibitors10aCanada10aDenmark10aUnited Kingdom10aCardiac Epidemiology10aepidemiology10aheart failure10ahypertension1 aE. Eworuke1 aM. Shinde1 aL. Hou1 aM. Paterson1 aP. Jensen1 aJ. Maro1 aA. Rai1 aD. Scarnecchia1 aD. Pennap1 aD. Woronow1 aR. Ghosh1 aS. Welburn1 aA. Pottegard1 aR. Platt1 aH. Lee1 aM. Bradley00aValsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study  a2023/04/18  ae0709850 v13  a2044-6055